Ann Woolley, MD
Infectious Disease · Boston, MANPI 1205157625
Payments from drug & device makers
Across 22 payments — averaging $1797.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- 60 Degrees Pharmaceuticals$28K
- Abbott$6K
- La Jolla Pharmaceutical Company$2K
- Philips North America LLC$1K
- Paragonix Technologies, Inc.$1K
- Intervascular$655
- plus $477 from 3 others
What the payments were for
- Consulting fees$9,72984%
- Speaking & faculty fees$1,0009%
- Travel & lodging$500%
- Food & beverage$8017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| 60 Degrees Pharmaceuticals | 2 | $27,973 |
| Abbott | 8 | $5,775 |
| La Jolla Pharmaceutical Company | 4 | $2,468 |
| Philips North America LLC | 2 | $1,205 |
| Paragonix Technologies, Inc. | 1 | $1,000 |
| Intervascular | 1 | $655 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $210 |
| United Therapeutics Corporation | 1 | $141 |
| Medtronic | 1 | $126 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate 3 Left Ventricular Dev$5,775
- Zevtera$2,290
- (9520) IGT Devices Undivided$1,155
- Sherpacool$1,000
- Shipper$1,000
- Canister$1,000
- InterGard$655
- Xerava$144
- LIVTENCITY$130
- HeartWare HVAD$126
How this compares
$39,553 in reported general payments places this provider in the 80th percentile of 368 infectious disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $56,230 |
| Vancomycin Hcl | 36 | $5,629 |
| Cefepime Hcl | 12 | $1,535 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Boston
- Dan BarouchBoston$35.8M
- Shahin LockmanBoston$7.4M
- Francisco MartyBoston$6.2M
- Stephen WalshBoston$5.4M
- Sophia KooBoston$4.9M
- David SnydmanBoston$2.6M
- Yoav GolanBoston$1.8M
- Todd EllerinBoston$1.7M
- Nicolas IssaBoston$1.3M
- Debra PoutsiakaBoston$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.